Cargando…

Ultrasound-Responsive Biomimetic Superhydrophobic Drug-Loaded Mesoporous Silica Nanoparticles for Treating Prostate Tumor

Interfacial nanobubbles on a superhydrophobic surface can serve as ultrasound cavitation nuclei for continuously promoting sonodynamic therapy, but their poor dispersibility in blood has limited their biomedical application. In this study, we proposed ultrasound-responsive biomimetic superhydrophobi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Qiaofeng, Chen, Dandan, Song, Yishu, Liu, Tianshu, Li, Wenqu, Chen, Yihan, Qin, Xiaojuan, Zhang, Li, Wang, Jing, Xie, Mingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146986/
https://www.ncbi.nlm.nih.gov/pubmed/37111641
http://dx.doi.org/10.3390/pharmaceutics15041155
_version_ 1785034708218806272
author Jin, Qiaofeng
Chen, Dandan
Song, Yishu
Liu, Tianshu
Li, Wenqu
Chen, Yihan
Qin, Xiaojuan
Zhang, Li
Wang, Jing
Xie, Mingxing
author_facet Jin, Qiaofeng
Chen, Dandan
Song, Yishu
Liu, Tianshu
Li, Wenqu
Chen, Yihan
Qin, Xiaojuan
Zhang, Li
Wang, Jing
Xie, Mingxing
author_sort Jin, Qiaofeng
collection PubMed
description Interfacial nanobubbles on a superhydrophobic surface can serve as ultrasound cavitation nuclei for continuously promoting sonodynamic therapy, but their poor dispersibility in blood has limited their biomedical application. In this study, we proposed ultrasound-responsive biomimetic superhydrophobic mesoporous silica nanoparticles, modified with red blood cell membrane and loaded with doxorubicin (DOX) (F-MSN-DOX@RBC), for RM-1 tumor sonodynamic therapy. Their mean size and zeta potentials were 232 ± 78.8 nm and −35.57 ± 0.74 mV, respectively. The F-MSN-DOX@RBC accumulation in a tumor was significantly higher than in the control group, and the spleen uptake of F-MSN-DOX@RBC was significantly reduced in comparison to that of the F-MSN-DOX group. Moreover, the cavitation caused by a single dose of F-MSN-DOX@RBC combined with multiple ultrasounds provided continuous sonodynamic therapy. The tumor inhibition rates in the experimental group were 71.5 8 ± 9.54%, which is significantly better than the control group. DHE and CD31 fluorescence staining was used to assess the reactive oxygen species (ROS) generated and the broken tumor vascular system induced by ultrasound. Finally, we can conclude that the combination of anti-vascular therapy, sonodynamic therapy by ROS, and chemotherapy promoted tumor treatment efficacy. The use of red blood cell membrane-modified superhydrophobic silica nanoparticles is a promising strategy in designing ultrasound-responsive nanoparticles to promote drug-release.
format Online
Article
Text
id pubmed-10146986
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101469862023-04-29 Ultrasound-Responsive Biomimetic Superhydrophobic Drug-Loaded Mesoporous Silica Nanoparticles for Treating Prostate Tumor Jin, Qiaofeng Chen, Dandan Song, Yishu Liu, Tianshu Li, Wenqu Chen, Yihan Qin, Xiaojuan Zhang, Li Wang, Jing Xie, Mingxing Pharmaceutics Article Interfacial nanobubbles on a superhydrophobic surface can serve as ultrasound cavitation nuclei for continuously promoting sonodynamic therapy, but their poor dispersibility in blood has limited their biomedical application. In this study, we proposed ultrasound-responsive biomimetic superhydrophobic mesoporous silica nanoparticles, modified with red blood cell membrane and loaded with doxorubicin (DOX) (F-MSN-DOX@RBC), for RM-1 tumor sonodynamic therapy. Their mean size and zeta potentials were 232 ± 78.8 nm and −35.57 ± 0.74 mV, respectively. The F-MSN-DOX@RBC accumulation in a tumor was significantly higher than in the control group, and the spleen uptake of F-MSN-DOX@RBC was significantly reduced in comparison to that of the F-MSN-DOX group. Moreover, the cavitation caused by a single dose of F-MSN-DOX@RBC combined with multiple ultrasounds provided continuous sonodynamic therapy. The tumor inhibition rates in the experimental group were 71.5 8 ± 9.54%, which is significantly better than the control group. DHE and CD31 fluorescence staining was used to assess the reactive oxygen species (ROS) generated and the broken tumor vascular system induced by ultrasound. Finally, we can conclude that the combination of anti-vascular therapy, sonodynamic therapy by ROS, and chemotherapy promoted tumor treatment efficacy. The use of red blood cell membrane-modified superhydrophobic silica nanoparticles is a promising strategy in designing ultrasound-responsive nanoparticles to promote drug-release. MDPI 2023-04-05 /pmc/articles/PMC10146986/ /pubmed/37111641 http://dx.doi.org/10.3390/pharmaceutics15041155 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jin, Qiaofeng
Chen, Dandan
Song, Yishu
Liu, Tianshu
Li, Wenqu
Chen, Yihan
Qin, Xiaojuan
Zhang, Li
Wang, Jing
Xie, Mingxing
Ultrasound-Responsive Biomimetic Superhydrophobic Drug-Loaded Mesoporous Silica Nanoparticles for Treating Prostate Tumor
title Ultrasound-Responsive Biomimetic Superhydrophobic Drug-Loaded Mesoporous Silica Nanoparticles for Treating Prostate Tumor
title_full Ultrasound-Responsive Biomimetic Superhydrophobic Drug-Loaded Mesoporous Silica Nanoparticles for Treating Prostate Tumor
title_fullStr Ultrasound-Responsive Biomimetic Superhydrophobic Drug-Loaded Mesoporous Silica Nanoparticles for Treating Prostate Tumor
title_full_unstemmed Ultrasound-Responsive Biomimetic Superhydrophobic Drug-Loaded Mesoporous Silica Nanoparticles for Treating Prostate Tumor
title_short Ultrasound-Responsive Biomimetic Superhydrophobic Drug-Loaded Mesoporous Silica Nanoparticles for Treating Prostate Tumor
title_sort ultrasound-responsive biomimetic superhydrophobic drug-loaded mesoporous silica nanoparticles for treating prostate tumor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146986/
https://www.ncbi.nlm.nih.gov/pubmed/37111641
http://dx.doi.org/10.3390/pharmaceutics15041155
work_keys_str_mv AT jinqiaofeng ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT chendandan ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT songyishu ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT liutianshu ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT liwenqu ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT chenyihan ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT qinxiaojuan ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT zhangli ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT wangjing ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor
AT xiemingxing ultrasoundresponsivebiomimeticsuperhydrophobicdrugloadedmesoporoussilicananoparticlesfortreatingprostatetumor